ETFs: Drug Pricing Policy Shapes PPH Risks in 2026
The VanEck PPH ETF faces two key risks in 2026: heavy concentration in Eli Lilly and shifting U.S. drug pricing polic...
This piece outlines scenarios where a lifecycle fund may be preferable to a target date fund, helping you tailor your retirement strategy.
23,259 articlesThe VanEck PPH ETF faces two key risks in 2026: heavy concentration in Eli Lilly and shifting U.S. drug pricing polic...
ARKK charges a 0.75% annual fee that quietly drags returns. This article explains the cost, contrasts with cheaper pe...
Two of the largest broad U.S. stock ETFs are in a low-cost clash. ITOT and VTI both offer broad exposure, but their f...
The Vanguard S&P 500 ETF (VOO) remains ultra-cheap, but a growing tech concentration within its holdings raises diver...
Morgan Stanley’s bitcoin ETF attracted $194 million in its first month, with no net daily outflows, signaling growing...
IBIT stands at a crossroads as Bitcoin volatility tests its spot-exposure structure. Two signals that will determine ...
Three ETFs can deliver roughly $37,000 a year on a $500,000 portfolio, providing about $3,100 a month without selling...
The SNPD ETF is widening its search for dividend growth by applying a 10-year growth screen to identify the next gene...
A standout move in the world of investing: a wealth manager makes a sizable bet on an active international rotation E...
Retail traders on Robinhood are flocking to a high-yield FANG income ETF, chasing monthly payouts even as upside is c...
Retirees cling to a low-cost dividend ETF that advisors often push, yet most seniors can’t recall the ticker. This re...
FNDF, the ETF tracking developed markets outside the U.S., pays semi-annual dividends funded by foreign cash flow. To...